Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00829010
First received: January 22, 2009
Last updated: March 13, 2014
Last verified: February 2014

January 22, 2009
March 13, 2014
February 2009
May 2011   (final data collection date for primary outcome measure)
Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 Microgram Per Millilitre (µg/mL). [ Time Frame: 1 month following primary immunization (post-Dose 3 at Month 3 for the HIV+/+ Group, HIV+/- Group, HIV- (3+1) Group, HIV- (EPI) Group and post-Dose 2 at Month 3 for the HIV- (2+1) Group) ] [ Designated as safety issue: No ]
Pneumococcal vaccine serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
Concentration of antibodies against the investigational vaccine above the protocol specified cut-off value [ Time Frame: One month after primary immunization ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00829010 on ClinicalTrials.gov Archive Site
  • Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes. [ Time Frame: 1 month following primary immunization (at Month 3) and 1 month after the booster vaccination (at Month 9) ] [ Designated as safety issue: No ]
    Concentrations were given in microgram per millilitre (µg/mL) and were expressed in geometric mean antibody concentrations. Pneumococcal vaccine serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Data were collected post-Dose 3 at Month 3 and post-Dose 4 at Month 9 for the HIV+/+, HIV+/-, HIV- (3+1) and HIV- (EPI) groups and post-Dose 2 at Month 3 and post-Dose 3 at Month 9 for the HIV- (2+1) Group. The cut-off of the assay was 0.05 µg/mL.
  • Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes. [ Time Frame: up to study end at Month 23 (24-27 months of age) ] [ Designated as safety issue: No ]
  • Opsonophagocytic Titers Against Vaccine Pneumococcal Serotypes. [ Time Frame: 1 month following primary immunization (at Month 3) and 1 month after the booster vaccination (at Month 9) ] [ Designated as safety issue: No ]
    Pneumococcal vaccine serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Data were collected post-Dose 3 at Month 3 and post-Dose 4 at Month 9 for the HIV+/+, HIV+/-, HIV- (3+1) and HIV- (EPI) groups and post-Dose 2 at Month 3 and post-Dose 3 at Month 9 for the HIV- (2+1) Group. Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay is an opsonic titer of 8.
  • Opsonophagocytic Titers Against Vaccine Pneumococcal Serotypes. [ Time Frame: up to study end at Month 23 (24-27 months of age) ] [ Designated as safety issue: No ]
  • Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A. [ Time Frame: 1 month following primary immunization (at Month 3) and 1 month after the booster vaccination (at Month 9) ] [ Designated as safety issue: No ]
    Concentrations were given in microgram per millilitre (µg/mL) and were expressed in geometric mean antibody concentrations. Cross-reactive pneumococcal vaccine serotypes assessed were 6A and 19A. Data were collected post-Dose 3 at Month 3 and post-Dose 4 at Month 9 for the HIV+/+, HIV+/-, HIV- (3+1) and HIV- (EPI) groups and post-Dose 2 at Month 3 and post-Dose 3 at Month 9 for the HIV- (2+1) Group. The cut-off of the assay was 0.05 µg/mL.
  • Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A. [ Time Frame: up to study end at Month 23 (24-27 months of age) ] [ Designated as safety issue: No ]
  • Opsonophagocytic Titers Against Cross-reactive Pneumococcal Serotypes 6A and 19A. [ Time Frame: 1 month following primary immunization (at Month 3) and 1 month after the booster vaccination (at Month 9) ] [ Designated as safety issue: No ]
    Cross-reactive pneumococcal vaccine serotypes assessed were 6A and 19A. Data were collected post-Dose 3 at Month 3 and post-Dose 4 at Month 9 for the HIV+/+, HIV+/-, HIV- (3+1) and HIV- (EPI) groups and post-Dose 2 at Month 3 and post-Dose 3 at Month 9 for the HIV- (2+1) Group. Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay is an opsonic titer of 8.
  • Opsonophagocytic Titers Against Cross-reactive Pneumococcal Serotypes 6A and 19A. [ Time Frame: up to study end at Month 23 (24-27 months of age) ] [ Designated as safety issue: No ]
  • Concentrations of Antibodies Against Protein D (PD) by Enzyme Linked ImmunoSorbent Assay (ELISA). [ Time Frame: 1 month following primary immunization (at Month 3) and 1 month after the booster vaccination (at Month 9) ] [ Designated as safety issue: No ]
    Concentrations of antibodies are presented as geometric mean concentrations expressed as Enzyme-Linked Immuno-Sorbent Assay (ELISA) units per millilitre (EL.U/mL). Data were collected post-Dose 3 at Month 3 and post-Dose 4 at Month 9 for the HIV+/+, HIV+/-, HIV- (3+1) and HIV- (EPI) groups and post-Dose 2 at Month 3 and post-Dose 3 at Month 9 for the HIV- (2+1) Group.
  • Concentrations of Antibodies Against Protein D (PD) by Enzyme-Linked ImmunoSorbent Assay (ELISA). [ Time Frame: up to study end at Month 23 (24-27 months of age) ] [ Designated as safety issue: No ]
  • Concentrations of Antibodies Against Diphtheria Toxoid (DT) and Tetanus Toxoid (TT). [ Time Frame: 1 month following primary immunization (at Month 3) ] [ Designated as safety issue: No ]
    Concentrations of antibodies are presented as geometric mean concentrations expressed as International units per millilitre (IU/mL).
  • Concentrations of Antibodies Against Diphtheria Toxoid (DT) and Tetanus Toxoid (TT). [ Time Frame: 1 month after the booster vaccination (at Month 9) ] [ Designated as safety issue: No ]
  • Concentrations of Antibodies Against Bordetella Pertussis (BP) by Enzyme Linked ImmunoSorbent Assay (ELISA). [ Time Frame: 1 month following primary immunization (at Month 3) ] [ Designated as safety issue: No ]
    Concentrations of antibodies are presented as geometric mean concentrations expressed as Enzyme-Linked Immuno-Sorbent Assay (ELISA) units per millilitre (EL.U/mL).
  • Concentrations of Antibodies Against Bordetella Pertussis (BP) by Enzyme-Linked ImmunoSorbent Assay (ELISA). [ Time Frame: 1 month after the booster vaccination (at Month 9) ] [ Designated as safety issue: No ]
  • Concentrations of Antibodies Against Polyribosyl-ribitol Phosphate (PRP) [ Time Frame: 1 month following primary immunization (at Month 3) ] [ Designated as safety issue: No ]
    Concentrations of antibodies are presented as geometric mean concentrations expressed as microgram per millilitre (µg/mL).
  • Concentrations of Antibodies Against Polyribosyl-ribitol Phosphate (PRP) [ Time Frame: 1 month after the booster vaccination (at Month 9) ] [ Designated as safety issue: No ]
  • Concentrations of Antibodies Against Hepatitis B Surface Antigen (HBs) by Enzyme Linked ImmunoSorbent Assay (ELISA). [ Time Frame: 1 month following primary immunization (at Month 3) ] [ Designated as safety issue: No ]

    Concentrations of antibodies are presented as geometric mean concentrations expressed as milli-International units per millilitre (mIU/mL).

    As a decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL), the table shows results following partial or complete retesting/reanalysis

  • Concentrations of Antibodies Against Hepatitis B Surface Antigen (HBs)by Enzyme-Linked ImmunoSorbent Assay (ELISA). [ Time Frame: 1 month after the booster vaccination (at Month 9) ] [ Designated as safety issue: No ]
  • Concentrations of Antibodies Against Rotavirus Immunoglobulin A (Rotavirus IgA), by Rotarix Vaccination Status. [ Time Frame: 1 month after the administration of the second vaccine dose (at Month 3) ] [ Designated as safety issue: No ]
    Concentrations of antibodies are presented as geometric mean concentrations expressed as units per millilitre (U/mL). Data were collected for subjects receiving 1, 2 doses or no Rotarix dose during the study.
  • Titers of Antibodies Against Measles [ Time Frame: 1 month following administration of the 1st and 2nd vaccine dose (at Months 9 and 15) ] [ Designated as safety issue: No ]
  • Salivary Antibodies Against Selected Common Bacterial Protein Antigens. [ Time Frame: up to study end at Month 23 (24-27 months of age) ] [ Designated as safety issue: No ]
  • Prevalence of Haemophilus Influenzae and/or Streptococcus Pneumoniae (Vaccine Serotypes, Cross-reactive or Other Serotypes) and Other Bacterial Pathogens in the Nasopharynx. [ Time Frame: up to study end at Month 23 (24-27 months of age) ] [ Designated as safety issue: No ]
  • Acquisition of New S. Pneumoniae and/or H. Influenzae Strains. [ Time Frame: up to study end at Month 23 (24-27 months of age) ] [ Designated as safety issue: No ]
  • Number of Subjects With Any and Severe (Grade 3) Solicited Local Adverse Events (AEs). [ Time Frame: During the 4-day (Days 0-3) post-primary vaccination period ] [ Designated as safety issue: No ]
    Solicited local AEs assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimetre.
  • Number of Subjects With Any, Severe (Grade 3) and Related Solicited General Adverse Events (AEs). [ Time Frame: During the 4-day (Days 0-3) post-primary vaccination period ] [ Designated as safety issue: No ]

    General AEs = diarrhoea, drowsiness, irritability, loss of appetite, vomiting and fever (axillary ≥ 37.5 degrees Celsius). Any= Incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3:

    drowsiness = prevented normal activity. irritability = crying that could not be comforted/ prevented normal activity. loss of appetite = not eating at all. diarrhoea: ≥ 6 looser than normal stools/day. vomiting: ≥ 3 episodes of vomiting/day. Fever = > 39.5°C Related = symptom assessed by the investigator as related to the vaccination.

  • Number of Subjects With Any and Severe (Grade 3) Solicited Local Adverse Events (AEs). [ Time Frame: During the 4-day (Days 0-3) period following booster vaccination with Synflorix vaccine ] [ Designated as safety issue: No ]
    Solicited local AEs assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimetre.
  • Number of Subjects With Any, Severe (Grade 3) and Related Solicited General Adverse Events (AEs). [ Time Frame: During the 4-day (Days 0-3) period following booster vaccination with Synflorix vaccine ] [ Designated as safety issue: No ]

    Solicited general AEs = drowsiness, irritability, loss of appetite and fever (axillary ≥ 37.5 degrees Celsius). Any= Incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3:

    drowsiness = prevented normal activity. irritability = crying that could not be comforted/ prevented normal activity. loss of appetite = not eating at all. Fever = temperature > 39.5°C Related = symptom assessed by the investigator as related to the vaccination.

  • Number of Subjects With Unsolicited AEs. [ Time Frame: Within the 31-day (Days 0-30) post-primary vaccination period ] [ Designated as safety issue: No ]
    An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
  • Number of Subjects With Unsolicited AEs. [ Time Frame: Within the 31-day (Days 0-30) post Synflorix booster vaccination period ] [ Designated as safety issue: No ]
    An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
  • Number of Subjects With Serious Adverse Events (SAEs). [ Time Frame: From study start (at Month 0) up to 1 month after Synflorix booster vaccination (up to Month 9) ] [ Designated as safety issue: No ]
    SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
  • Number of Subjects With Serious Adverse Events (SAEs). [ Time Frame: From study start at Month 0 (6 weeks of age and above) up to study end at Month 23 (24-27 months of age) ] [ Designated as safety issue: No ]
  • Concentration of antibodies against components of the investigational vaccine for additional parameters [ Time Frame: One month following primary and booster vaccination and up to study end ] [ Designated as safety issue: No ]
  • Concentration of antibodies against components of the co-administered vaccine [ Time Frame: One month after primary and booster immunization ] [ Designated as safety issue: No ]
  • Concentration of antibodies against the co-administered measles vaccine [ Time Frame: One month after the first and second vaccine dose ] [ Designated as safety issue: No ]
  • Occurrence of S. pneumoniae and H. influenzae in the nasopharynx [ Time Frame: At the time of analysis ] [ Designated as safety issue: No ]
  • Occurrence of each solicited adverse event [ Time Frame: Within 4 days after each vaccination ] [ Designated as safety issue: No ]
  • Occurrence of unsolicited adverse events [ Time Frame: Within 31 days after each vaccination ] [ Designated as safety issue: No ]
  • Occurrence of serious adverse events [ Time Frame: Following screening or after the first vaccination, as applicable, up to study end. ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
Primary and Booster Vaccination Course in Human Immunodeficiency Virus (HIV) Infected Infants, HIV Exposed Uninfected Infants and Unexposed Uninfected Infants Receiving the Pneumococcal Vaccine GSK 1024850A.

The purposes of this study:

  • To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants following a 3-dose primary vaccination at 6, 10 and 14 weeks of age and following booster vaccination at 9-10 months of age.
  • To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV unexposed uninfected infants receiving either a 3-dose primary vaccination according to the EPI vaccination schedule at 6, 10 and 14 weeks of age with or without booster vaccination at 9-10 months of age or a 2-dose primary vaccination at 6 and 14 weeks of age followed by booster vaccination at 9-10 months of age.
  • This study also aims to assess the impact of the pneumococcal vaccine GSK1024850A on nasopharyngeal carriage of S. pneumoniae and H. influenzae up to 24 months of age in all study participants.

This protocol posting has been updated according to Protocol amendment 1, December 08

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Infections, Streptococcal
  • Biological: Pneumococcal vaccine GSK1024850A
    Intramuscular injection, administered as 3 or 4 doses
  • Biological: Tritanrix-HepB/Hib
    Intramuscular injection, 4 doses
    Other Name: DTPw-HBV/Hib
  • Biological: measles
    Intramuscular injection, 2 doses
  • Biological: Rotarix
    Oral, 2 doses
    Other Names:
    • HRV
    • Human rotavirus
  • Biological: Local OPV
    Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
    Other Name: oral poliovirus vaccine
  • Experimental: HIV+/+ Group
    Infants born from a HIV positive mother and confirmed as HIV infected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered intramuscularly in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
    Interventions:
    • Biological: Pneumococcal vaccine GSK1024850A
    • Biological: Tritanrix-HepB/Hib
    • Biological: measles
    • Biological: Rotarix
    • Biological: Local OPV
  • Experimental: HIV+/- Group
    Infants born from a HIV positive mother and confirmed as HIV exposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
    Interventions:
    • Biological: Pneumococcal vaccine GSK1024850A
    • Biological: Tritanrix-HepB/Hib
    • Biological: measles
    • Biological: Rotarix
    • Biological: Local OPV
  • Experimental: HIV- (3+1) Group
    Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
    Interventions:
    • Biological: Pneumococcal vaccine GSK1024850A
    • Biological: Tritanrix-HepB/Hib
    • Biological: measles
    • Biological: Rotarix
    • Biological: Local OPV
  • Experimental: HIV- (EPI) Group
    Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 3 primary doses of Synflorix™ vaccine (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
    Interventions:
    • Biological: Pneumococcal vaccine GSK1024850A
    • Biological: Tritanrix-HepB/Hib
    • Biological: measles
    • Biological: Rotarix
    • Biological: Local OPV
  • Experimental: HIV- (2+1) Group
    Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 2 primary doses (at 6 & 14 weeks of age at study Months 0 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
    Interventions:
    • Biological: Pneumococcal vaccine GSK1024850A
    • Biological: Tritanrix-HepB/Hib
    • Biological: measles
    • Biological: Rotarix
    • Biological: Local OPV
  • Koen A et al. Immunogenicity of oral live attenuated human rotavirus vaccine given as two doses (10 and 14 weeks) in HIV‐infected, HIV‐exposed‐uninfected and HIV‐unexposed‐uninfected infants in South Africa. Abstract presented at the 19th International AIDS Conference (IAC), Washington DC, USA, 22‐27 July 2012.
  • Mahdi S et al. Vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine [PHiD-CV] according to different schedules in healthy South African children. Abstract presented at the 30th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Thessaloniki, Greece, 8-12 May 2012.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
484
August 2012
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects between, and including 6-10 weeks of age at the time of the first vaccination.
  • Subjects for whom the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol.
  • Written informed consent obtained from the parent(s)/guardian(s) of the child/ward.
  • Free of any known or suspected health problems (as established by medical history and clinical examination before entering into the study).

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of the study vaccines, or planned use during the study period.
  • A family history of hereditary immunodeficiency other than HIV infection.
  • Major congenital defects or serious chronic illness other than HIV infection.
  • For HIV infected infants: Moderately and severely symptomatic: stages III and IV according to latest version of WHO classification.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and/or Streptococcus pneumoniae.
  • History of, or intercurrent, diphtheria, tetanus, pertussis, and Haemophilus influenzae type b disease.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • History of any neurological disorders or seizures.
  • Acute disease at the time of enrolment.
  • Babies for which weight for age is < 3rd percentile at Visit 1, using standard growth charts, with the exception of HIV infected infants for which the decision of enrolment was left to the investigator's discretion.
  • Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal (GI) tract, intussusception (IS) or other medical condition determined to be serious by the investigator.
  • Gastroenteritis within 7 days preceding the study vaccine administration (warrants deferral of vaccination).
Both
6 Weeks to 10 Weeks
Yes
Contact information is only displayed when the study is recruiting subjects
South Africa
 
NCT00829010
111634
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP